08:30 AM EDT, 05/08/2025 (MT Newswires) -- Aptose Biosciences ( APTOF ) on Thursday reported a narrower first-quarter loss as research and operating expenses fell.

The company, which is trialling its lead candidate tuspetinib as part of a combination therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), said net loss narrowed to $5.5 million, or $2.61 per share, from $9.6 million, or $22.02 per share, in the prior year period.

Research and development expenses fell about $4.1 million, to $2.3 million, while operating expenses dipped to $5.5 million, from $9.8 million.